Management Platform
Our OTRIX Platform
The Otolabs experts work tirelessly to develop drugs that can prevent or reverse the effects of this condition and improve the quality of life for those affected. Our approach not only includes cutting-edge research and development, but also a comprehensive management platform to track existing and new drugs. Our platform integrates with medical APIs, ensuring medical compliance and providing the latest information on drug interactions and side effects. By utilizing the latest technology and resources, Otological is committed to providing patients with effective and safe treatments for ear-related diseases. Let us help you on the journey to better hearing health
Example of a drug workflow using our platform
E3 Ligase Whole-Body Atlas
We have identified the expression profile of approximately 600 naturally-occurring unique E3 ligases across different tissues. This knowledge enables us to match a target protein with the appropriate E3 ligase based on expression, distribution, intracellular localization, and biology.
E3 Ligase Whole-Body Atlas
We have identified the expression profile of approximately 600 naturally-occurring unique E3 ligases across different tissues. This knowledge enables us to match a target protein with the appropriate E3 ligase based on expression, distribution, intracellular localization, and biology.
E3 Ligase Binders Toolbox
Our E3 Ligase Whole-Body Atlas has allowed us to generate a toolbox of proprietary ligands designed to bind to an expanded library of E3 ligases that we believe will enable us to develop novel small molecule protein degraders with specific degradation profiles.
E3 Ligase Binders Toolbox
Our E3 Ligase Whole-Body Atlas has allowed us to generate a toolbox of proprietary ligands designed to bind to an expanded library of E3 ligases that we believe will enable us to develop novel small molecule protein degraders with specific degradation profiles.
Ternary Complex Modeling
Our structural biology information, combined with biochemical, biophysical, and computational characterization of ternary complexes is used to prospectively design highly efficient, selective, and potent degraders.
Ternary Complex Modeling
Our structural biology information, combined with biochemical, biophysical, and computational characterization of ternary complexes is used to prospectively design highly efficient, selective, and potent degraders.
Quantitative System Pharmacology Model
Our understanding of the in vitro and in vivo pharmacokinetic/ pharmacodynamic, or PK/PD, relationships of our degraders across different tissues and cell types has allowed us to build an understanding of the diverse parameters that impact protein levels, and to model these parameters in different species, including humans.
Quantitative System Pharmacology Model
Our understanding of the in vitro and in vivo pharmacokinetic/ pharmacodynamic, or PK/PD, relationships of our degraders across different tissues and cell types has allowed us to build an understanding of the diverse parameters that impact protein levels, and to model these parameters in different species, including humans.
Proprietary Chemistry
Our expertise in uncovering the molecular principles responsible for the properties of these new class of small molecules provides us the opportunity to design degraders with optimized pharmaceutical properties tailored to not only specific diseases but also potentially targeted patient populations.
Proprietary Chemistry
Our expertise in uncovering the molecular principles responsible for the properties of these new class of small molecules provides us the opportunity to design degraders with optimized pharmaceutical properties tailored to not only specific diseases but also potentially targeted patient populations.
